MPMustafa Tufan Pehlivan

Mustafa Tufan Pehlivan

*This is an algorithmically generated author record based on publicly available information.

Mustafa Tufan Pehlivan has a total of 2 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • AI-Powered Patient Education and Triage Tools in Community Neurosurgery

    by Kenan Şimşek, Serhat Hızal, Mustafa Tufan Pehlivan

    AI in neurosurgery has been largely described from the perspective of well-resourced academic centers. Yet most of the global neurosurgical workforce practices in community and state hospitals without institutional data-science infrastructure. This chapter presents an implementation case study of an AI-integrated platform designed, built, and deployed by a practicing neurosurgeon at a Turkish state hospital, with cross-institutional analysis from co-authors at two Turkish settings. The system combines an LLM chatbot configured for Turkish-language neurosurgical queries, 48 interactive patient-facing tools, a rule-based treatment-decision interface for lumbar and cervical disc pathology, and automated content-generation pipelines. The authors describe system architecture, linguistic adaptation, ethical considerations under KVKK, cost structure, and implementation lessons.

  • Open Access

    Intrawound vancomycin powder for the prevention of surgical site infection in cranial neurosurgery: a narrative review

    by Mustafa Tufan Pehlivan, Serhat Hızal, Kenan Şimşek

    Background: Surgical site infections (SSIs) following cranial neurosurgical procedures contribute to significant morbidity, prolonged hospitalisation and healthcare expenditure. Intrawound vancomycin powder (IVP), extensively investigated in spinal surgery, has been increasingly applied as a prophylactic adjunct in cranial neurosurgery. However, the supporting evidence is methodologically limited and inconsistent, comprising predominantly retrospective single-centre studies with conflicting findings across procedure types, the retraction of two influential meta-analyses in April 2025 and the recent publication of the first large randomised controlled trial (RCT)—all of which mandate a critical re-appraisal of current practice. Objective: This narrative review synthesises the current evidence regarding the efficacy, safety and clinical application of IVP for SSI prevention following cranial neurosurgery, with attention to procedure-specific outcomes, dosing considerations, controversies and knowledge gaps. Methods: A comprehensive narrative literature search was performed in PubMed/MEDLINE, Scopus and Web of Science for English-language studies published between January 2000 and March 2026 evaluating IVP use in cranial neurosurgery. Randomised trials, cohort studies, systematic reviews and meta-analyses were included and synthesised by procedure type. Results: Observational evidence has been associated with reduced SSI rates following craniotomy with IVP; however, the first adequately powered RCT, by Kannan and colleagues ( n = 1,103), demonstrated no significant difference between treatment and control groups (3.94% versus 4.10%; p = 0.90), and the suggestion of greater benefit in higher-risk subgroups is not consistently supported. Findings in cranioplasty remain markedly conflicting, with some studies reporting near-elimination of SSI and others showing no benefit. Data on deep brain stimulation (DBS) and ventriculoperitoneal (VP) shunt surgery are sparse and inconclusive. Reported doses range from 500 mg to 2 g, with minimal systemic absorption and a favourable safety profile. A large retrospective study of 987 nonmalignant cranial procedures further questioned routine IVP prophylaxis in low-risk populations. Conclusion: IVP is a pharmacologically rational, low-cost and generally well-tolerated adjunct that may have a role in SSI prevention in selected cranial procedures. However, the heterogeneity of evidence, the negative first RCT and the absence of adequately powered confirmatory trials preclude universal adoption. A risk-stratified, procedure-specific approach is prudent until more robust evidence emerges.

  • Early lumbar microdiscectomy and quality-of-life outcomes: methodological considerations regarding the pilot study by Horan et al.

    by Kenan Şimşek, Serhat Hızal, Mustafa Tufan Pehlivan

    Horan and colleagues recently reported a pilot study examining quality-of-life outcomes following early versus late elective lumbar microdiscectomy, concluding that surgery within twelve months is associated with superior patient-reported outcomes and proposing a six-month maximum waiting time. While the clinical question is both relevant and timely, we believe several methodological and conceptual issues merit discussion before such a recommendation is translated into practice. First, the study conflates waitlist time with symptom duration, yet its Discussion and proposed threshold are predominantly grounded in literature examining the latter. Second, only 38 of 64 eligible patients (59%) were included in the analysis, with no characterisation of non-responders, and the postoperative assessment window varied from ten to thirty-four months, introducing substantial noise into between-group comparisons. Third, the absence of preoperative baseline scores precludes calculation of minimal clinically important differences and leaves the authors' conclusions vulnerable to baseline imbalance. Fourth, the authors' own data reveal a cost and complication paradox: the early group experienced a longer length of stay, a higher median cost, and a ten per cent cerebrospinal-fluid leak rate versus zero per cent in the late group-findings that directly oppose the cost-consequence literature invoked in support of their thesis. Finally, the study period coincided with the COVID-19 pandemic, which substantially altered surgical throughput and perioperative pathways across Europe; this temporal confounding is neither acknowledged nor adjusted for. A robust answer to this important question will require a prospective design with capture of symptom duration, preoperative and standardised-interval postoperative outcome measures, an a priori sample-size calculation, formal characterisation of non-responders, and adjustment for era-related confounders.

  • Open Access

    Methodological Considerations on the Retrospective Cohort Study of Remifentanil-Propofol versus Propofol Alone in Severe Traumatic Brain Injury [Letter]

    by Kenan Şimşek, Serhat Hızal, Mustafa Tufan Pehlivan

    Letter for the article Remifentanil-Propofol versus Propofol Alone in Patients with Severe Traumatic Brain Injury: A Retrospective Cohort Study on Anesthesia Outcomes

  • Open Access

    Methodological Considerations on the Reported Association Between Postoperative Chronic Back Pain Syndrome and Psychiatric, Brain, and Mortality Outcomes in a Korean Nationwide Cohort [Letter]

    by Kenan Şimşek, Serhat Hızal, Mustafa Tufan Pehlivan

    Letter for the article Impact of Postoperative Chronic Back Pain Syndrome on the Incidence of Psychiatric and Brain Disorders, and All-Cause Mortality